- Text-only version of this website
- Skip navigation
- Home page
- What's new
- Search
- Contact Webmaster
- Website policies
- Disability services
Dr. Winterstein installed as president-elect of the International Society for Pharmacoepidemiology
As president-elect, Almut Winterstein will serve on the executive board and chair the strategic planning committee. She joined ISPE in 2000 and has held numerous leadership roles during the past two decades.
Dr. Josh Brown receives NIH Loan Repayment Award and ambassador appointment
As a loan repayment awardee, Brown will receive financial support paying off his student debt, in return for a commitment to engage in NIH mission-relevant research.
Study finds that short-term use of azithromycin is not associated with increased risk of hearing loss
The researchers reviewed medical claims for around half million adults in 29 states who had used either azithromycin or amoxicillin during a 10 year period.
Diabetes, Obesity and Metabolism journal publishes grad student Ghadeer Dawwas’ SGLT2 inhibitors article
The study suggests that SGLT2 inhibitors are safe and effective in treatment of patients with type II diabetes.
Dr. Josh Brown appointed as associate editor of BMC Cardiovascular Disorders and Editorial Advisory Board of JMCP
These service appointments are the first for Brown, who joined the college in 2016.
We’re Heading to Prague for ICPE 2018
August 22 – 26, 2018: Please take a look at the schedule for our department’s oral and poster presentations at the 34th annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Welcome to the Department of Pharmaceutical Outcomes and Policy
Thank you for your interest in our program. We are proud of our outstanding faculty, graduate students, fellows and staff who possess a passion and commitment to both teaching and research.
The Department of Pharmaceutical Outcomes and Policy includes a broad range of programs and resources. Faculty is actively engaged in the entry-level PharmD program and its own graduate program, including about 25 PhD students, a small number of residential and more than 150 online MS students.
The Department’s focus in research and graduate training is centered on the evaluation of drugs and related medical technology. This focus includes classic pharmacoepidemiologic and pharmacoeconomic work in areas such as drug safety and comparative effectiveness, as well as patient safety and program evaluation as related to medication use. We have excellent facilities for quantitative research including a data center with a state-of the art 32TB privacy-approved research server and a variety of billing record and clinical research databases.
UF Health, the largest fully integrated academic health center in the Southeast with all six health colleges on campus, allows broad interdisciplinary collaboration as well as access to a fully integrated electronic health record system. Our graduate program admits students each fall semester and we frequently offer fellowship and internship opportunities.
Almut G. Winterstein, Ph.D.
Department Chair
Events
POP Seminar Announcement: Patrick Squires and Xinyi (Rose) Jiang
The UF College of Pharmacy Department of Pharmaceutical Outcomes and Policy welcomes Patrick Squires and Xinyi (Rose) Jiang as our September 13th, 2018 POP research seminar presenters. Patrick received his bachelor’s degree in […]
POP Seminar Announcement: Dr. Amie Goodin and Dr. Vassiki Sanogo
The UF College of Pharmacy Department of Pharmaceutical Outcomes and Policy welcomes Amie Goodin, Ph.D. and Vassiki Sanogo, Ph.D. as our August 30th, 2018 POP research seminar presenters. Dr. Goodin currently […]